Ann: Race further strengthens Clinical Advisory Board, page-12

I always thought that Bisantrene would still work as a single agent, but I thought it might be difficult to convince doctors to use it on its own (all cancer treatments are combination these days). I could see that the NPP wasn’t working (along with the rest of the market) so this wasn’t exactly news. Combination trials were the obvious way to go.

What really attracted me to Bisantrene was the breast cancer Phase III trial. The more I read that paper the more I could see what a potential gold mine Bisantrene could be. I knew that cardiotoxicity was a huge problem in breast cancer and that a drug that worked as well as the existing anthracyclines, but without the cardiotoxicity, would be in huge demand by doctors and by extension large pharma.

The 5-Path strategy was not my idea alone. It came about more from me coming into the company with fresh perspective and questioning all the assumptions everyone was making. The 5-Path strategy was the result of everyone in the team working together to answering the question if we focus on achieving a pharma transaction, how could we best maximise the value of Bisantrene. The more I have been involved the more excited by the prospects of Bisantrene I have become.